Literature DB >> 28395565

Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.

Neel K Gupta1, Chia-Ching Wang1,2, Gabriel N Mannis1, John-Paul J Yu3, James L Rubenstein1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28395565      PMCID： PMC6026016          DOI： 10.1080/10428194.2017.1312374

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

Review 1.  Acquired immunodeficiency syndrome-related lymphoma.

Authors:  A M Levine
Journal:  Blood       Date:  1992-07-01       Impact factor: 22.113

2.  Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?

Authors:  Maria Christina Cox; Giuseppe Mannino; Luana Lionetto; Virginia Naso; Maurizio Simmaco; Maria Antonietta Aloe Spiriti
Journal:  Am J Hematol       Date:  2011-11       Impact factor: 10.047

3.  Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

Authors:  H Lim; L Kane; J B Schwartz; C S Hesdorffer; S G Deeks; N Greig; L Ferrucci; E J Goetzl
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

4.  Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

Authors:  James L Rubenstein; Patrick A Treseler; Paul J Stewart
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

5.  Trust in physicians and racial disparities in HIV care.

Authors:  Somnath Saha; Elizabeth A Jacobs; Richard D Moore; Mary Catherine Beach
Journal:  AIDS Patient Care STDS       Date:  2010-07       Impact factor: 5.078

6.  Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS.

Authors:  C Jacomet; P M Girard; M G Lebrette; V L Farese; L Monfort; W Rozenbaum
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

7.  Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care.

Authors:  Michael J Silverberg; Wendy Leyden; Charles P Quesenberry; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2009-07-16       Impact factor: 5.128

8.  Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Valter Torri; Christopher P Fox; Paul La Rosée; Elisabeth Schorb; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Angela Ferrari; Kim M Linton; Roberta Rudà; Mascha Binder; Tobias Pukrop; Monica Balzarotti; Alberto Fabbri; Peter Johnson; Jette Sønderskov Gørløv; Georg Hess; Jens Panse; Francesco Pisani; Alessandra Tucci; Stephan Stilgenbauer; Bernd Hertenstein; Ulrich Keller; Stefan W Krause; Alessandro Levis; Hans J Schmoll; Franco Cavalli; Jürgen Finke; Michele Reni; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2016-04-06       Impact factor: 18.959

9.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

10.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more
  2 in total

Review 1.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Authors:  Yujia Zhai; Xiangxiang Zhou; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-04       Impact factor: 5.485
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.